On 13 January 2026, Sino Biopharmaceutical Limited (“Sino Biopharmaceutical”, stock code: 01177.HK) announced its proposal to acquire 100% of the equity interests in Hygieia through its wholly owned subsidiary. Upon completion of the proposed acquisition, Hygieia will become an indirect, wholly owned subsidiary of Sino Biopharmaceutical. The maximum base consideration for the transaction is CNY 1.2 billion (subject to reduction), which will be settled partly in cash and partly by consideration shares. Deal completion is contingent upon certain conditions precedent being satisfied.

Hygieia is a pioneering biopharmaceutical enterprise specializing in the research and development of innovative drugs for small interfering ribonucleic acids (siRNAs). It has built an integrated innovative drug development system that spans target discovery to clinical proof-of-concept (POC). Its research focuses on three major chronic disease areas: weight management and metabolism, cardiovascular and cerebrovascular diseases, and neurological disorders.

Fangda Partners acted as PRC legal counsel to Sino Biopharmaceutical in the transaction. It provided comprehensive legal services and advice to the purchaser and other transaction parties. Those legal services included transaction structuring, legal due diligence, and drafting and negotiating the transaction documents. The corporate team on the transaction was led by partners Josh SHIN, Susie SHI and Henry HE. Key team members included Claire LI, counsel Muriel HE and Leon LU, associates Ethel WANG, Barlow LIU, BO Jiarui, and trainee ZHANG Shuyan. The intellectual property team on the transaction was led by partner SUN Muran. Key team members included LU Liang, Herman ZHANG, Jerome FU and Robin ZHANG.